EPHB2 and neoplasm: While cabozantinib inhibited MET and ERK activities, it did not affect the AKT/mTOR pathway, and a combination of cabozantinib and mTOR inhibitior MLN0128 potentiated tumor regression in the MET/β-catenin-driven HCC model, suggesting that this combination might have a potential to overcome primary cabozantinib resistance [51].